18 results on '"Gadgeel, S.M."'
Search Results
2. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.
3. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD).
4. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC.
5. 1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)
6. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
7. 1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses.
8. 2061 - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders.
9. The Selective Personalized Radioimmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes.
10. 1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer.
11. 1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC.
12. The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT).
13. 1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD).
14. 1302P Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression.
15. Interplay of Cardiac and Pulmonary Toxicity: An Analysis of Prospective Trials for Locally Advanced Non-Small Cell Lung Cancer.
16. Differential Role of Soy Isoflavones in Radiotherapy of Lung Cancer: Augmenting Tumor Response and Protecting Normal Tissue
17. Fast Neutron Radiotherapy for Advanced Stage Non-small Cell Lung Cancer
18. Salvage Fast Neutron Radiotherapy for Treatment of Refractory Non-small Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.